US Patent

US11260038 — Methods and compositions for treating edema refractory to oral diuretics

Method of Use · Assigned to RESQ Pharmaceuticals LLC · Expires 2040-12-04 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods and compositions for administering bumetanide through intranasal, sublingual, and subcutaneous routes to treat edema that does not respond to oral diuretics.

USPTO Abstract

The present invention features methods and compositions for the intranasal, sublingual, and subcutaneous administration of bumetanide for the treatment of subjects suffering from edema refractory to oral diuretics.

Drugs covered by this patent

Bumex (BUMETANIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4279`	—	Bumex

Patent Metadata

Patent number: US11260038
Jurisdiction: US
Classification: Method of Use
Expires: 2040-12-04
Drug substance claim: No
Drug product claim: No
Assignee: RESQ Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.